RxDoctor Payments DataLook up a doctor →

Justin Mendel, MD

Gastroenterology · Atlanta, GANPI 1669791836

Payments from drug & device makers

$69,974in general payments, 2019–2025

Across 476 payments — averaging $147.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$56K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$687
  • Bristol Myers Squibb$452
  • Johnson & Johnson$403
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$5,00036%
  • Travel & lodging$7295%
  • Food & beverage$8,08158%
  • Education$2342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,974 in reported general payments places this provider in the 90th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$187,794
Medicare patients
432
Services billed
3,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase17$47,071
LinzessLinaclotide47$42,703
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates150$9,975
Dexlansoprazole DrDexlansoprazole14$4,834
Lansoprazole44$4,753
Mesalamine11$4,323
Pantoprazole Sodium145$2,483
Budesonide DrBudesonide18$2,452
Colestipol Hcl21$2,321
Omeprazole143$1,118
Famotidine87$1,014
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$527
Ondansetron OdtOndansetron44$504
Dicyclomine Hcl18$301
Mirtazapine14$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,834$89,77464 claims
SandozLansoprazole$163$4,75344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →